Antitumor efficacy of a urokinase activation-dependent anthrax toxin

Molecular Cancer Therapeutics

Volumn 5, Issue 1, 2006, Pages 89-96

  Rønø, Birgitte ^a   Rømer, John ^b   Liu, Shihui ^c   Bugge, Thomas H ^d   Leppla, Stephen H ^c   Kristjansen, Paul E G ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX TOXIN; DEXAMETHASONE; PRODRUG; UROKINASE; UROKINASE RECEPTOR; VETRANAL; ANTINEOPLASTIC AGENT; BACTERIAL ANTIGEN; BACTERIAL TOXIN; HYBRID PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; EXPERIMENTAL NEOPLASM; FIBROSARCOMA; GENE OVEREXPRESSION; INTESTINE MUCOSA; LEWIS CARCINOMA; LIVER TOXICITY; LUNG TOXICITY; MALE; MELANOMA; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; SPLEEN DISEASE; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CHEMISTRY; DRUG EFFECT; ENZYME ACTIVATION; METABOLISM; MOUSE;

ANIMALS; ANTIGENS, BACTERIAL; ANTINEOPLASTIC AGENTS; BACTERIAL TOXINS; CARCINOMA, LEWIS LUNG; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; MALE; MICE; MICE, INBRED C57BL; PRODRUGS; RECOMBINANT FUSION PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 33644866858     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0163     Document Type: Article

References (46)

1. Dano K, Romer J, Nielsen BS, et al. Cancer invasion and tissue remodeling - cooperation of protease systems and cell types. APMIS 1999;107:120-7.
2. Andreasen PA, Egelund R, Petersen HH. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000;57:25-40.
3. Andreasen PA, Kjoller L, Christensen L, Duffy MJ. The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 1997;72:1-22.
4. Sidenius N, Blasi F. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 2003;22:205-22.
5. Behrendt N. The urokinase receptor (uPAR) and the uPAR-associated protein (uPARAP/Endo180): membrane proteins engaged in matrix turnover during tissue remodeling. Biol Chem 2004;385:103-36.
6. Ploug M. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor. Curr Pharm Des 2003;9:1499-528.
7. Romer J, Nielsen BS, Ploug M. The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 2004;10:2359-76.
8. Liu S, Bugge TH, Leppla SH. Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J Biol Chem 2001;276:17976-84.
9. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc Natl Acad Sci U S A 2003;100:657-62.
10. Scobie HM, Rainey GJ, Bradley KA, Young JA. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc Natl Acad Sci U S A 2003;100:5170-4.
11. St Croix B, Rago C, Velculescu V, et al. Genes expressed in human tumor endothelium. Science 2000;289:1197-202.
12. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA. Identification of the cellular receptor for anthrax toxin. Nature 2001; 414:225-9.
13. Bell SE, Mavila A, Salazar R, et al. Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling. J Cell Sci 2001;114:2755-73.
14. Gordon VM, Klimpel KR, Arora N, Henderson MA, Leppla SH. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect Immun 1995;63:82-7.
15. Abrami L, Liu S, Cosson P, Leppla SH, van der Goot FG. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J Cell Biol 2003;160:321-8.
16. Singh Y, Klimpel KR, Goel S, Swain PK, Leppla SH. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect Immun 1999;67:1853-9.
17. Milne JC, Furlong D, Hanna PC, Wall JS, Collier RJ. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J Biol Chem 1994;269:20607-12.
18. Mogridge J, Cunningham K, Lacy DB, Mourez M, Collier RJ. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc Natl Acad Sci U S A 2002;99:7045-8.
19. Ke SH, Coombs GS, Tachias K, Corey DR, Madison EL. Optimal subsite occupancy and design of a selective inhibitor of urokinase. J Biol Chem 1997;272:20456-62.
20. Arora N, Klimpel KR, Singh Y, Leppla SH. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J Biol Chem 1992;267:15542-8.
21. Romer J, Bugge TH, Pyke C, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996;2:287-92.
22. Lund LR, Bjorn SF, Sternlicht MD, et al. Lactational competence and involution of the mouse mammary gland require plasminogen. Development 2000;127:4481-92.
23. Spang-Thomsen M, Nielsen A, Visfeldt J. Growth curves of three human malignant tumors transplanted to nude mice. Exp Cell Biol 1980;48:138-54.
24. Bhakoo HS, Paolini NS, Milholland RJ, Lopez RE, Rosen F. Glucocorticoid receptors and the effect of glucocorticoids on the growth of B16 melanoma. Cancer Res 1981;41:1695-701.
25. Jankun J, Keck RW, Skrzypczak-Jankun E, Swiercz R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res 1997;57:559-63.
26. Alonso DF, Tejera AM, Farias EF, Bal de Kier JE, Gomez DE. Inhibition of mammary tumor cell adhesion, migration, and invasion by the selective synthetic urokinase inhibitor B428. Anticancer Res 1998;18:4499-504.
27. Zeslawska E, Jacob U, Schweinitz A, Coombs G, Bode W, Madison E. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors. J Mol Biol 2003;328:109-18.
28. Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, St Croix B. Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 2001;61:6649-55.
29. Pyke C, Kristensen P, Ralfkiaer E, et al. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 1991;138: 1059-67.
30. Pyke C, Ralfkiaer E, Ronne E, Hoyer-Hansen G, Kirkeby L, Dano K. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer. Histopathology 1994;24:131-8.
31. Pyke C, Graem N, Ralfkiaer E, et al. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 1993;53:1911-5.
32. Grondahl-Hansen J, Ralfkiaer E, Kirkeby LT, Kristensen P, Lund LR, Dano K. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 1991; 138:111-7.
33. Nielsen BS, Sehested M, Timshel S, Pyke C, Dano K. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 1996;74: 168-77.
34. Pyke C, Salo S, Ralfkiaer E, Romer J, Dano K, Tryggvason K. Laminin-5 is a marker of invading cancer cells in some human carcinomas and is coexpressed with the receptor for urokinase plasminogen activator in budding cancer cells in colon adenocarcinomas. Cancer Res 1995;55: 4132-9.
35. Luther T, Magdolen V, Albrecht S, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol 1997;150: 1231-44.
36. Romer J, Pyke C, Lund LR, Ralfkiaer E, Dano K. Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin. J Invest Dermatol 2001;116:353-8.
37. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000;156:567-75.
38. Yoshida E, Tsuchiya K, Sugiki M, Sumi H, Mihara H, Maruyama M. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation 1996;20:319-26.
39. Kristensen P, Eriksen J, Blasi F, Dano K. Two alternatively spliced mouse urokinase receptor mRNAs with different histological localization in the gastrointestinal tract. J Cell Biol 1991;115:1763-71.
40. Larsson LI, Skriver L, Nielsen LS, Grondahl-Hansen J, Kristensen P, Dano K. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol 1984;98:894-903.
41. Gibson PR, Birchall I, Rosella O, et al. Urokinase and the intestinal mucosa: evidence for a role in epithelial cell turnover. Gut 1998;43: 656-63.
42. Hanks S, Adams S, Douglas J, et al. Mutations in the gene encoding capillary morphogenesis protein 2 cause juvenile hyaline fibromatosis and infantile systemic hyalinosis. Am J Hum Genet 2003;73:791-800.
43. Bonuccelli G, Sotgia F, Frank PG, et al. Anthrax toxin receptor (ATR/TEM8) is highly expressed in epithelial cells lining the toxin's three sites of entry (lung, skin, and intestine). Am J Physiol Cell Physiol 2005;6:1402-10.
44. Duesbery NS, Resau J, Webb CP, et al. Suppression of ras-mediated transformation and inhibition of tumor growth and angiogenesis by anthrax lethal factor, a proteolytic inhibitor of multiple MEK pathways. Proc Natl Acad Sci U S A 2001;98:4089-94.
45. Skriver L, Larsson LI, Kielberg V, et al. Immunocytochemical localization of urokinase-type plasminogen activator in Lewis lung carcinoma. J Cell Biol 1984;2:752-7.
46. Solberg H, Lober D, Eriksen J, et al. Identification and characterization of the murine cell surface receptor for the urokinase-type plasminogen activator. Eur J Biochem 1992;2052:451-8.